Loomis, Sayles & Company’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.5M | Buy |
206,382
+12,494
| +6% | +$815K | 0.02% | 311 |
|
|
2025
Q1 | $13M | Sell |
193,888
-297
| -0.2% | -$19.9K | 0.02% | 307 |
|
|
2024
Q4 | $10.7M | Buy |
194,185
+19,568
| +11% | +$1.08M | 0.01% | 358 |
|
|
2024
Q3 | $10.4M | Sell |
174,617
-6,831
| -4% | -$408K | 0.01% | 353 |
|
|
2024
Q2 | $11.6M | Buy |
181,448
+1,105
| +0.6% | +$70.4K | 0.02% | 338 |
|
|
2024
Q1 | $12.5M | Sell |
180,343
-86
| -0% | -$5.95K | 0.02% | 324 |
|
|
2023
Q4 | $9.95M | Buy |
180,429
+15,200
| +9% | +$838K | 0.02% | 336 |
|
|
2023
Q3 | $9.59M | Sell |
165,229
-3,426
| -2% | -$199K | 0.02% | 340 |
|
|
2023
Q2 | $9.08M | Buy |
168,655
+64,643
| +62% | +$3.48M | 0.01% | 355 |
|
|
2023
Q1 | $4.13M | Buy |
+104,012
| New | +$4.13M | 0.01% | 408 |
|
|
2018
Q4 | – | Sell |
-108
| Closed | -$6K | – | 843 |
|
|
2018
Q3 | $6K | Hold |
108
| – | – | ﹤0.01% | 869 |
|
|
2018
Q2 | $7K | Hold |
108
| – | – | ﹤0.01% | 848 |
|
|
2018
Q1 | $6K | Hold |
108
| – | – | ﹤0.01% | 850 |
|
|
2017
Q4 | $7K | Sell |
108
-300
| -74% | -$19.4K | ﹤0.01% | 808 |
|
|
2017
Q3 | $21K | Buy |
408
+31
| +8% | +$1.6K | ﹤0.01% | 750 |
|
|
2017
Q2 | $18K | Buy |
377
+256
| +212% | +$12.2K | ﹤0.01% | 764 |
|
|
2017
Q1 | $6K | Buy |
121
+18
| +17% | +$893 | ﹤0.01% | 845 |
|
|
2016
Q4 | $6K | Hold |
103
| – | – | ﹤0.01% | 883 |
|
|
2016
Q3 | $7K | Hold |
103
| – | – | ﹤0.01% | 818 |
|
|
2016
Q2 | $6K | Sell |
103
-24
| -19% | -$1.4K | ﹤0.01% | 809 |
|
|
2016
Q1 | $4K | Sell |
127
-119
| -48% | -$3.75K | ﹤0.01% | 947 |
|
|
2015
Q4 | $11K | Buy |
+246
| New | +$11K | ﹤0.01% | 845 |
|